Post treatment outcome and quality of life in patients with inoperable advanced gastric carcinoma
DOI:
https://doi.org/10.18203/2320-6012.ijrms20230310Keywords:
Carcinoma, Gastric, Capecitabine, Oxaliplatin, CisplatinAbstract
Background: The outcome of treatment for advanced gastric carcinoma can vary depending on a number of factors, including the stage and aggressiveness of the cancer, the patient's overall health, and their response to treatment. In general, the prognosis is poor, with a median overall survival of less than one year. Quality of life (QOL) is an important consideration for patients with advanced gastric carcinoma, as they may experience a range of symptoms such as pain, fatigue, and difficulty eating. This study aimed to evaluate the post-treatment outcomes and QOL in patients with inoperable advanced gastric carcinoma after treatment with cisplatin-capecitabine and with oxaliplatin-capecitabine.
Methods: This Quasi-experimental study was conducted at the department of oncology, Bangabandhu Sheikh Mujib medical university, Dhaka, Bangladesh. The study duration was 1 year, from February 2021 to March 2022. During this period, a total of 64 cases of advanced gastric cancer were divided in two equal groups, arm A who had received cisplatin capecitabine, and arm B who received oxaliplatin capecitabine.
Result: The mean age at diagnosis was 55.85 and 56.76 respectively. The majority of the patients, 43.8% in arm A and 50% in arm B, ranged in age from 61 to 70. The gender distribution was similar, 78% and 69% of patients in arm A and B respectively were male. Both groups had the majority of patients receiving an ECOG performance rating of 2, with 68.8% in arm A and 59.4% in arm B, and the liver being the most common metastatic site for 56.3% in arm A and 50.0% in arm B. The most frequent risk factor was Helicobacter pylori infection, observed in 68.8% of arm A and 78.1% of arm B. The most common primary tumor site was the antrum, with 50% and 53.1% patients in arm A and B respectively had the primary tumor in the antrum of the stomach.
Conclusions: In inoperable advanced gastric cancer, the cisplatin-capecitabine regimen is equally effective as oxaliplatin-capecitabine in terms of disease outcome. Furthermore, the cisplatin-capecitabine regimen is less costly than the combination of oxaliplatin-capecitabine, and provides almost similar QOL. As a result, the cisplatin-capecitabine regimen could be utilized as an alternate choice in patients who are unable to afford an oxaliplatin-based regimen.
References
Cancer. Available at: https://www.who.int/health-topics/cancer. Accessed on December 5, 2022.
Stomach cancer statistics. WCRF International. Available at: https://www.wcrf.org/cancer-trends/stomach-cancer-statistics/. Accessed on December 5, 2022.
Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38.
Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. eClin Med. 2022;47.
Stomach Cancer-Statistics. Cancer.Net. 2012. Available at: https://www.cancer.net/cancer-types/stomach-cancer/statistics. Accessed on December 5, 2022.
DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. Lippincott Williams and Wilkins. 2008;1748.
Lewandowska A, Rudzki G, Lewandowski T, Próchnicki M, Rudzki S, Laskowska B et al. Quality of Life of Cancer Patients Treated with Chemotherapy. Int J Environ Res Public Heal. 2020;17(19):6938.
Zheng C, Gao ZM, Huang HB, Li K, Liu XF. Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(5):2299-312.
Peng J, Tan C, Zeng X, Liu S. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. PLoS One. 2018;13(6):e0199553.
Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14(1):50-5.
Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: An overview. Eur J Surg Oncol. 2010;36(8):709-17.
Khuroo MS, Zargar SA, Mahajan R, Banday MA. High incidence of oesophageal and gastric cancer in Kashmir in a population with special personal and dietary habits. Gut. 1992;33(1):11-5.
Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5(1):5-11.
Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 2010;14(4):302-8.
Lee YY, Derakhshan MH. Environmental and Lifestyle Risk Factors of Gastric Cancer. Arch Iran Med. 2013;16(6).
Haruma KK, Kamada T, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori Infection Is a Major Risk Factor for Gastric Carcinoma in Young Patients. Scand J Gastroenterol. 2000;35(3):255-9.
Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002;13(12):1893-8.
Moon K, Chung CK, Jahng TA, Kim HJ, Kim C. Postoperative Survival and Ambulatory Outcome in Metastatic Spinal Tumors: Prognostic Factor Analysis. J Kor Neurosurgical Soci. 2011;50:216-23.